- Home
- DXR vs MDAI Comparison
DXR vs MDAI Comparison
Compare DXR & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- MDAI
- Stock Information
- Founded
- DXR 1970
- MDAI 2013
- Country
- DXR United States
- MDAI United States
- Employees
- DXR N/A
- MDAI N/A
- Industry
- DXR Medical/Dental Instruments
- MDAI Medical/Dental Instruments
- Sector
- DXR Health Care
- MDAI Health Care
- Exchange
- DXR Nasdaq
- MDAI Nasdaq
- Market Cap
- DXR 46.9M
- MDAI 51.9M
- IPO Year
- DXR N/A
- MDAI N/A
- Fundamental
- Price
- DXR $13.00
- MDAI $2.46
- Analyst Decision
- DXR Strong Buy
- MDAI Strong Buy
- Analyst Count
- DXR 1
- MDAI 1
- Target Price
- DXR $25.00
- MDAI $3.50
- AVG Volume (30 Days)
- DXR 6.1K
- MDAI 820.8K
- Earning Date
- DXR 01-01-0001
- MDAI 11-05-2025
- Dividend Yield
- DXR N/A
- MDAI N/A
- EPS Growth
- DXR 3.46
- MDAI N/A
- EPS
- DXR 0.36
- MDAI N/A
- Revenue
- DXR $66,306.00
- MDAI $27,549,000.00
- Revenue This Year
- DXR N/A
- MDAI N/A
- Revenue Next Year
- DXR N/A
- MDAI $60.05
- P/E Ratio
- DXR $35.22
- MDAI N/A
- Revenue Growth
- DXR N/A
- MDAI 22.27
- 52 Week Low
- DXR $6.55
- MDAI $1.01
- 52 Week High
- DXR $14.00
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- DXR 57.62
- MDAI 55.66
- Support Level
- DXR $12.70
- MDAI $2.21
- Resistance Level
- DXR $14.00
- MDAI $2.80
- Average True Range (ATR)
- DXR 0.52
- MDAI 0.20
- MACD
- DXR -0.13
- MDAI 0.02
- Stochastic Oscillator
- DXR 50.00
- MDAI 49.25
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.